PT - JOURNAL ARTICLE AU - Desta, Beza Zewdu AU - Derseh, Behailu Tariku AU - Dadi, Abel Fekadu TI - Mortality and predictors of Chronic Kidney Diseases (CKD) in selected dialysis centers in Addis Ababa, Ethiopia AID - 10.1101/2022.01.27.22269879 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.27.22269879 4099 - http://medrxiv.org/content/early/2022/01/29/2022.01.27.22269879.short 4100 - http://medrxiv.org/content/early/2022/01/29/2022.01.27.22269879.full AB - Background Chronic Kidney Disease (CKD) affects 10-15% of the population worldwide. The number of dialysis patients is steadily rising in Ethiopia. Chronic hemodialysis patients experience high rates of mortality; however, data is lacking in Ethiopia. We explored the mortality and its driving factors in selected dialysis center in Addis AbabaMethod we retrospectively followed a group of End-Stage Renal Disease patients on hemodialysis from 2016 to2020 in St. Paul Millennium Medical College (SPMMC), Zewditu Memorial Hospital (ZMH), and Menellik II Hospital. We fitted Kaplan Meier analysis to estimate the one and five year’s survival probability of these patients and Cox Proportional regression analysis to model the predictors of mortality at p value ≤0.05.Result We analyzed a data of (139) patients under follow up. The mean age (± SD) of the patients was 36.8 (±11.95) years. Twenty-four (17%) of the patients died at the end of follow-up. The median survival time was 46.2 months (95% CI: 41.8, 50.5). The one and five-year’s survival probability of these patients was 64.8% and 18.7%, respectively. Our analysis showed that patients with hypertension (AHR = 4.33; 95% CI: 1.02, 34.56), cardiac complication (AHR = 4.69; 95% CI: 1.32, 16.8), and infection during dialysis (AHR = 3.89; 95% CI: 1.96, 13.8) were more likely to die.Conclusion The survival status of hemodialysis patients in three was low. Preventing and treating comorbidities and complication during dialysis would reduce mortality of CKD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was obtained from the Ethical Review Committee of Debre Berhan University, College of Health Sciences (Protocol number: 12/21/CHS/SPH). Permission was obtained from all Hospitals and Dialysis Centers. Confidentiality and privacy of the information were assured and maintained by preventing disclosure of the information to third parties.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files